Neogen Corp is develop, manufacture and market a diverse line of products and services dedicated to food and animal safety. Its Food Safety segment consists mainly of diagnostic test kits and complementary products (e.g., culture media) sold to food and animal feed producers and processors to preserve the safety and quality of food to prevent contamination and foodborne illnesses such as foodborne pathogens, spoilage organisms, natural toxins, food allergens, and ruminant by-products. These products also ensure the general hygiene of the food manufacturing environment. It also have products to determine food quality and nutritional components. Its segments are Food, Animal safety. Majority of revenue comes from Food Safety. It has presence in United states, and International market.
Last trade$10.94
Day change+$0.055 (+0.51%)
Day range$10.75 – $11.20
Volume750,381
Market cap$2.38B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$2.38B
Price / earnings
—
Price / book
1.14×
Price / sales
2.69×
EV / sales
3.37×
EV / EBITDA
27.35×
Profitability
Earnings per share
-$0.26
Return on assets
-1.7%
Return on equity
-2.69%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.37×
Current ratio
4.1×
Quick ratio
3.07×
Cash ratio
1.21×
Cash flow
Price / cash flow
27.86×
Price / free cash flow
47.74×
Free cash flow
$49.75M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for NEOG, quarterly periods
Line item
Q1 FY2027 Aug 31, 2026
Q4 FY2026 May 31, 2026
Q3 FY2026 Feb 28, 2026
Q2 FY2026 Nov 30, 2025
Q1 FY2026 Aug 31, 2025
Q4 FY2025 May 31, 2025
Q3 FY2025 Feb 28, 2025
Q2 FY2025 Nov 30, 2024
Revenue
$222.8M
$225.3M
$211.2M
$224.69M
$209.2M
$225.5M
$221M
$231.26M
Cost of revenue
$117.3M
$117.5M
$112.2M
$118.01M
$114.2M
$132.6M
$110.7M
$117.93M
Gross profit
$105.5M
$107.8M
$99M
$106.68M
$95M
$92.9M
$110.3M
$113.33M
Selling, general and administrative
$100.8M
$99.8M
$98.5M
$107.5M
$106M
$99.9M
$100.4M
$104.32M
Research and development
$6.5M
$4.9M
$3.8M
$4.56M
$5.1M
$6.3M
$4.5M
$5.11M
Total operating expenses
$107.3M
$104.7M
$102.3M
$112.06M
$111.1M
$704.1M
$104.9M
$570.81M
Operating income
-$1.8M
$3.1M
-$3.3M
-$5.38M
-$16.1M
-$611.2M
$5.4M
-$457.48M
Interest expense
-$13.8M
-$13.9M
-$13.9M
-$14.85M
-$15.5M
-$16.5M
-$17M
-$18.14M
Income before taxes
-$14.9M
-$12.1M
-$20.3M
-$20.36M
$43.8M
-$631.2M
-$9.7M
-$476.57M
Income taxes
-$3M
-$800K
-$3.3M
-$4.44M
$7.5M
-$19M
$1.2M
-$20.29M
Net income
-$11.9M
-$11.3M
-$17M
-$15.92M
$36.3M
-$612.2M
-$10.9M
-$456.28M
Net income attributable to common shareholders
-$11.9M
-$11.3M
-$17M
-$15.92M
$36.3M
-$612.2M
-$10.9M
-$456.28M
EBITDA
$27.3M
$32.5M
$25.62M
$23.55M
$13M
$17M
$34.75M
$33.96M
Basic earnings per share
-$0.05
-$0.05
-$0.08
-$0.07
$0.17
-$2.82
-$0.05
-$2.10
Diluted earnings per share
-$0.05
-$0.05
-$0.08
-$0.07
$0.17
-$2.82
-$0.05
-$2.10
Recent news
Company coverage with links to the original publishers.
Neogen (NEOG) reported strong Q1 fiscal 2027 results with earnings and revenue beating consensus estimates and raised full-year guidance. However, analyst estimates have shifted downward by 33.33% in the past month. The stock carries a Zacks Rank #3 (Hold) with a C aggregate VGM Score, suggesting in-line returns ahead despite recent 6.7% outperformance versus the S&P 500.
The FDA issued a warning letter to Neogen Corporation on September 29, 2026, following an investigation linking its veterinary wound care product Neogen Vet HYCOAT to at least 20 horse deaths due to contamination. The incident represents the largest number of horse deaths associated with a quality defect in an FDA-regulated veterinary product. Neogen initiated a voluntary recall in January 2026. The announcement triggered a 7.22% stock price decline. Pomerantz LLP is investigating potential securities fraud claims on behalf of investors.
Pomerantz LLP is investigating potential securities fraud claims against Neogen Corporation following an FDA warning letter regarding its veterinary wound care product HYCOAT, which was linked to at least 20 horse deaths—the largest number of deaths associated with a quality defect in an FDA-regulated veterinary product. Neogen initiated a voluntary recall in January 2026, and the stock fell 7.22% on the news.
Pomerantz LLP is investigating securities fraud claims on behalf of investors of Rafael Holdings, Inc. after the company announced that its Phase 3 clinical trial for Trappsol Cyclo failed to achieve statistical significance on its primary endpoint. Rafael's stock price fell 34.98% following the announcement on September 30, 2026. The law firm is also investigating similar claims against FMC Corporation and Neogen Corporation.
Neogen Corporation (NEOG) and Where Food Comes From, Inc. (WFCF) are compared as investment opportunities in the food safety and agricultural verification sectors. NEOG demonstrates stronger growth momentum with 6.5% revenue growth, improving margins, and strategic initiatives like Petrifilm manufacturing transition and Genomics divestiture to reduce debt. WFCF offers a more conservative balance sheet with improving profitability but faces challenges from slow revenue growth and heavy exposure to the struggling U.S. cattle industry. NEOG is positioned better for growth-focused investors despite higher debt, while WFCF appeals to conservative investors seeking stability.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.